On Tuesday the 16th and Wednesday the 17th of April, the European Medicines Agency (EMA) hosted a meeting in Amsterdam, “Multi-stakeholder workshop on psychedelics – Towards an EU regulatory framework”.
Heavy rain and strong winds earlier in the week stunted Schiphol Airport’s capacity, making it a bad trip for some. Still, those attendees that made it to Amsterdam included academics, representatives from drug developers, lawyers, and so on.
Here, we don’t aim to provide a blow-by-blow account of the meeting, but instead share some thematic notes. I also focus more on the Q&A or interactive elements of the workshop, as those are generally where new information or angles are found.
In this Dispatch:
Regulatory Remits
Disentangling Pharmacotherapy from Psychotherapy
Standardisation and Its Discontents
Standardising Extra-Pharmacological Elements of Psychedelic Studies
Standardising Adverse Event Definition and Reporting
Blinding
Indication Sequencing: TRD vs. MDD
Safety & Post-Trial Support
Relationship Between Subjective Effects and Therapeutic Outcomes
Deficiencies in Present Data
Predicting Treatment Response
Rescheduling
Incentivising Psychedelic Drug Development in the EU
Please sign in to your Pα+ account to read the full article…
This article is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
Select organisations mentioned in this article: Cybin; Compass Pathways; GH Research; PsyPAN; PsyPal; EFPIA; PAREA; Clerkenwell Health; Lykos Therapeutics; European Medicines Agency (EMA); Food and Drug Administration (FDA).
